The Food and Drug Administration has ordered every maker of a GLP-1 drug to warn about a rare form of sudden vision loss. Black adults are among the people most likely to be taking them: in a 2024 KFF poll, 18% of Black adults said they had ever used one, against 10% of white adults and 13% of Hispanic adults.
The FDA announced the labeling change on Nov. 9. It covers Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and the rest of the class, and it adds the condition, non-arteritic anterior ischemic optic neuropathy (NAION), to the Warnings and Precautions section. NAION happens when blood flow drops to the optic nerve. It can cause permanent vision loss in one eye.
The risk is small. In the FDA’s analysis of 126 randomized trials covering 134,253 patients, NAION occurred in 6.4 of every 100,000 people a year on a GLP-1 drug, against 3.8 per 100,000 among people on a placebo or other diabetes drugs. Real-world data the agency reviewed showed higher rates, 30 to 32 events per 100,000 person-years. The FDA says the underlying cause “isn’t understood.”
What patients are told to do is specific. Anyone who notices sudden, painless blurring, blind spots or other changes in one eye, often on waking, should contact a health professional immediately and get an eye exam. A patient who develops NAION should talk with their doctor about whether to stay on the drug. Nobody is being told to stop taking it on their own.
Why this reaches Black patients
KFF, citing CDC data, notes that Black and Hispanic adults have higher obesity rates than white adults, which is the reason it gives for the gap in use. The poll was fielded April 23 to May 1, 2024, among 1,479 adults. The margin of error is 3 points for the full sample and 9 points among the 189 people who reported using a GLP-1, so the 18% and 10% are estimates, not exact counts.
The announcement, as reported, gives no breakdown of NAION cases by race. That is the missing piece. If more Black patients are taking these drugs, the public deserves to know whether they are affected differently, and the label change does not answer it. Race data should be part of the FDA’s follow-up on this warning, and drugmakers should be asked to report it.
The warning is also a reason to protect eye care, not to scare anyone off a medicine that treats diabetes. That means insurers covering the exam, and doctors telling patients the symptoms before a prescription is filled, not after. Updated labels are due from the manufacturers.
Have your say